The triple-negative breast cancer (TNBC) cell line MDA-MB-468 was used for ChIP experiments because it has an endogenous p53-R273H mutation (arginine to histidine mutation at position 273) [6], while the R273H mutation is a missense mutation in the DNA-binding domain and is the third most common mutation in p53 in human cancers [7]. This evidence concerns the gene TP53 and cancer.